Literature DB >> 12439556

Complete response to radiation therapy in a patient with chemotherapy-resistant ovarian clear cell adenocarcinoma.

N Takai1, H Utsunomiya, Y Kawano, K Nasu, H Narahara, I Miyakawa.   

Abstract

Recurrent ovarian cancer after front-line chemotherapy is incurable. In most institutions, chemotherapy is continued as salvage therapy after primary chemotherapy failure and despite the fact that long-term survival and complete responses are infrequent. Radiation therapy for patients with recurrent ovarian cancer has often been done with palliative intent. A patient with ovarian clear cell adenocarcinoma received irradiation with palliative intent to the whole pelvis after chemotherapy (paclitaxel, carboplatin, and irinotecan) produced no effect. Although she developed a rectovaginal fistula due to cancer invasion during radiation therapy. One year and half after the therapy, she is still alive with no evidence of disease. In an effort to maximize salvage potential and quality of life while minimizing toxicity, selected patients with ovarian cancer should be treated with radiation therapy directed to residual or recurrent sites.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12439556     DOI: 10.1007/s00404-001-0258-3

Source DB:  PubMed          Journal:  Arch Gynecol Obstet        ISSN: 0932-0067            Impact factor:   2.344


  2 in total

1.  Short response duration even in responders to chemotherapy using conventional cytotoxic agents in recurrent or refractory clear cell carcinomas of the ovary.

Authors:  Masashi Takano; Tomoko Goto; Masafumi Kato; Naoki Sasaki; Morikazu Miyamoto; Kenichi Furuya
Journal:  Int J Clin Oncol       Date:  2012-05-03       Impact factor: 3.402

2.  Primary peritoneal clear cell carcinoma treated with IMRT and interstitial HDR brachytherapy: a case report.

Authors:  Skyler B Johnson; Joann I Prisciandaro; Jessica Zhou; Scott W Hadley; R Kevin Reynolds; Shruti Jolly
Journal:  J Appl Clin Med Phys       Date:  2014-01-06       Impact factor: 2.102

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.